Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Fertility Centers Of Illinois Crystal Lake Location Expands To Offer Holistic Treatments
Fertility Centers of Illinois (FCI), Crystal Lake location - part of one of the nation"s leading infertility treatment practices - has expanded its services to include an array of holistic treatments such as acupuncture, massage and nutrition counseling, in addition to free patient education seminars. FCI recognizes the growing benefits of integrating holistic therapies with medical treatment and with an increasing demand from patients, has extended its partnership with Pulling Down The Moon to create the first holistic center located within the fertility clinic. Don't forget to buy zoloft online no prescription.

Patient Upside Murky In Drug-Price Cases
"The prices of hundreds of brand-name drugs are about to be cut 4%, and millions of Americans may soon receive a check in the mail as compensation for having overpaid for their prescriptions," but "the extent to which the average consumer will benefit isn"t yet clear," the Wall Street Journal reports. "The price cuts and expected payments are the result of federal class-action settlements involving two drug-price publishers and a major drug wholesaler that were accused of inflating drug prices."

generic viagra online


News of the day
Prospective Evaluation Finds High Levels Of Satisfaction With ConvaTec Moldable Skin Barrier
Enterostomal therapy nurses and people living with an ostomy reported very high levels of satisfaction with a new moldable skin barrier pioneered by ConvaTec Ostomy Care, according to results from a prospective evaluation published this month in the journal Ostomy Wound Management.
Sexual Health

Dynavax Awarded Grant To Support Development Of TLR Inhibitors In Skin Diseases

Dynavax Technologies Corporation (Nasdaq:DVAX) announced the award of a Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID). This grant will support the preclinical development of Dynavax"s first-in-class oligonucleotide-based Toll-like Receptor (TLR) inhibitors for use in inflammatory skin diseases such as psoriasis, cutaneous lupus, and dermatomyositis. This new two-year $700,000 grant is in addition to a $1.8 million grant awarded in 2008. "In addition to validating our proprietary technology, this new grant supports the preclinical studies for our TLR inhibitors, which represent a novel therapeutic approach for the treatment of inflammatory skin disorders," commented Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer of Dynavax Technologies. "Grant funding and partnerships with leading pharmaceutical companies help us advance the development of our TLR-based products targeting significant unmet medical needs." For more information about Dynavax"s TLR inhibitor program, visit here. Dynavax Technologies Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009